- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01265745
Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects
A Phase I, Double-blind, Randomized, Placebo Controlled, Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) as a 120 Minute Infusion in Healthy, Normal Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66223
- Quintiles Phase I Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1.Subject must have read, understood, and provided written informed consent 2.Subjects should be in generally good health, based upon pre-study medical history, physical examination, laboratory testing and ECG 3.Laboratory screening values (i.e., hematology, clinical chemistries and urinalysis tests) must be within study-defined ranges 4.No detectable antibody to B. anthracis Protective Antigen (PA-IgG) as measured by ELISA testing at study Screening 5.Women of childbearing potential and sexually active males may be enrolled if protocol specific contraceptives or practices are met 6.Agreement to not receive any vaccinations Day -1 through to 29 days post dosing. Vaccination against B. anthracis is prohibited during the study.8.Body Mass Index (BMI) ≥ 19 and ≤ 30. 9. Abstinence from alcohol for 24 hours prior to study drug
Exclusion Criteria:
1. Prior known or suspected exposure to B. anthracis 2. Prior vaccination for B. anthracis 3.Prior exposure to Valortim as part of a previous clinical trial 4.Immunoglobulin E (IgE) level at screening that is above the upper limit of normal per the laboratory's reference range 5. History of drug or alcohol abuse, i.e., having been treated either in an in-patient or out-patient facility within 12 months of study Screening 6. Outward signs of active allergies or upper respiratory infection 7. History of dizziness or fainting upon standing (orthostatic hypotension) which, in the opinion of the Investigator, may interfere with safety evaluations 8. Positive drug result and/or positive alcohol result at time of study Screening or at Day -1
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Valortim
Valortim 1mg,5mg,10mg
|
a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5.
A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution.
The vial is sealed with a 20 mm stopper and white flip-off seal.
|
Placebo Comparator: Placebo
Saline solution will be used as the placebo
|
Equivalent amounts to subjects weight, once over 120 minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 133 days
|
|
133 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics
Time Frame: 133 days
|
Evaluation of the pharmacokinetics/pharmacodynamics of Valortim in healthy human volunteers
|
133 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ralph Schutz, MD, Quintiles Phase I Services
- Study Director: Valeire D Riddle, MD, Sponsor Medical Monitor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0036-10-01
- HHSN272200700033C (Other Identifier: HHSN)
- BAA-NIH-NIAID-DMID-07-37 (Other Grant/Funding Number: BAA-NIH-NIAID-DMID-07-37)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anthrax
-
Emergent BioSolutionsCompletedAnthrax InfectionUnited States
-
Elusys TherapeuticsCompletedInhalational AnthraxUnited States
-
Elusys TherapeuticsCompletedInhalational AnthraxUnited States
-
Elusys TherapeuticsCompletedInhalational AnthraxUnited States
-
Elusys TherapeuticsCompletedInhalational AnthraxUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedBacillus Anthracis (Anthrax)United States
-
National Institute of Allergy and Infectious Diseases...Terminated
-
PharmAthene UK LimitedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacillus Anthracis (Anthrax)United States
-
Emergent BioSolutionsDepartment of Health and Human ServicesCompletedSymptoms of Inhalational AnthraxUnited States